Search Results - "REGALADO, Lorna V"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

    Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas by Reardon, David A, Akabani, Gamal, Coleman, R Edward, Friedman, Allan H, Friedman, Henry S, Herndon, 2nd, James E, Cokgor, Ilkcan, McLendon, Roger E, Pegram, Charles N, Provenzale, James M, Quinn, Jennifer A, Rich, Jeremy N, Regalado, Lorna V, Sampson, John H, Shafman, Timothy D, Wikstrand, Carol J, Wong, Terence Z, Zhao, Xiao-Guang, Zalutsky, Michael R, Bigner, Darell D

    Published in Journal of clinical oncology (01-03-2002)
    “…To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

    Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas by REARDON, David A, AKABANI, Gamal, QUINN, Jennifer A, RICH, Jeremy N, REGALADO, Lorna V, SAMPSON, John H, SHAFMAN, Timothy D, WIKSTRAND, Carol J, WONG, Terence Z, ZHAO, Xiao-Guang, ZALUTSKY, Michael R, BIGNER, Darell D, COLEMAN, R. Edward, FRIEDMAN, Allan H, FRIEDMAN, Henry S, HERNDON, James E, COKGOR, Ilkcan, MCLENDON, Roger E, PEGRAM, Charles N, PROVENZALE, James M

    Published in Journal of clinical oncology (01-03-2002)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Phase II Trial of Murine 131 I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

    Phase II Trial of Murine 131 I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas by Reardon, David A., Akabani, Gamal, Edward Coleman, R., Friedman, Allan H., Friedman, Henry S., Herndon, James E., Cokgor, Ilkcan, McLendon, Roger E., Pegram, Charles N., Provenzale, James M., Quinn, Jennifer A., Rich, Jeremy N., Regalado, Lorna V., Sampson, John H., Shafman, Timothy D., Wikstrand, Carol J., Wong, Terence Z., Zhao, Xiao-Guang, Zalutsky, Michael R., Bigner, Darell D.

    Published in Journal of clinical oncology (01-03-2002)
    “…PURPOSE: To assess the efficacy and toxicity of intraresection cavity 131 I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: